BioSpace News Archive

United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment and a Leadership Circle sponsor at this year’s SNMMI, is making news on several fronts at SNMMI’s annual meeting in Chicago this week.

Innovent Biologics, Inc. and RemeGen Co., Ltd., announced that they entered into a clinical trial collaboration and supply agreement with for the combination therapies of TYVYT® with RC88, a novel mesothelin-targeting antibody-drug conjugate, or RC108, a novel c-Met-targeting ADC, respectively, as potential treatment options for advanced solid tumors in China.

This comes at a time when more than 37 million Americans live with diabetes, and nearly 90% of people with diabetes are overweight or have obesity.